1xbet 모바일 Pharmaceutical Co., Ltd.

REDWOOD CITY, CA, and TOKYO, JAPAN, July 5, 2012 - Proteus Digital Health, Inc. and 1xbet 모바일 Pharmaceutical Co., Ltd. announced they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize a new category of medicines. These new medicines will be based on 1xbet 모바일's pharmaceutical products and Proteus's digital health feedback system incorporating Proteus's novel sensor-based technologies. Under the agreement, Proteus and 1xbet 모바일 have entered an exclusive collaboration to develop commercial products in two defined therapeutic areas of high unmet medical need. 1xbet 모바일 has also been granted a non-exclusive license to utilize Proteus technology in its clinical research and development activities.

Financial terms of the agreement were not disclosed.

The Proteus digital health feedback system combines wearable 1xbet 모바일 ingestible sensor technologies that together are designed to help improve patients' health habits. Detailed information, including when a medication has been taken as well as activity 1xbet 모바일 rest patterns, is captured 1xbet 모바일 delivered to a secure database. The information, accessible from a variety of platforms such as mobile phones with consent granted by the patient, is designed to help patients 1xbet 모바일 their caregivers better manage their conditions 1xbet 모바일 to help clinicians provide more effective care.

About Proteus Digital 1xbet 모바일

Proteus Digital Health, formally known as Proteus Biomedical, Inc, believes in better health, powered by you. Proteus's wearable and ingestible sensor technology is used to deliver digital medications and other health and wellness products. Headquartered in Redwood City, CA, Proteus partners with and licenses to leading companies to commercialize digital health products, including 1xbet 모바일, Novartis, Avery Dennison, Medtronic,ON Semiconductor, Kaiser Permanente and Lloydspharmacy. For more information, please visitwww.proteusdigital1xbet 모바일.com.